Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140438 | 0.93 | PDE5A (0.51) | PDE5AADORA3KCNH2 | |
| SCHEMBL20161168 | 0.92 | PDE5A (0.51) | PDE5AADORA3KCNH2 | |
| SCHEMBL20141472 | 0.92 | PDE5A (0.50) | PDE5AADORA3KCNH2 | |
| SCHEMBL20139584 | 0.92 | PDE5A (0.44) | PDE5AADORA3KCNH2 | |
| SCHEMBL21787395 | 0.91 | PDE5A (0.49) | PDE5AADORA3KCNH2 | |
| SCHEMBL20140423 | 0.91 | PDE5A (0.51) | PDE5AADORA3KCNH2 | |
| SCHEMBL20139682 | 0.89 | PDE5A (0.42) | PDE5AADORA3KCNH2 | |
| SCHEMBL20140349 | 0.89 | PDE5A (0.49) | PDE5AADORA3KCNH2 | |
| SCHEMBL20140449 | 0.89 | PDE5A (0.40) | PDE5AADORA3KCNH2 | |
| SCHEMBL20161254 | 0.89 | PDE5A (0.40) | PDE5AADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | TISENTO THERAPEUTICS INC. | 2021-06-17 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885ADORA3 1070/4885KCNH2 2953/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885ADORA3 1070/4885KCNH2 2953/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885ADORA3 1070/4885KCNH2 2953/4885 |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | CS, COQ8A, GLS | PDE5A 187/4885ADORA3 3757/4885KCNH2 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.